AMESBURY, Mass., Aug. 23 /PRNewswire/ -- Fluidnet Corporation (www.fluidnet.net), an innovator of advanced intravenous (IV) infusion systems, announced today that its Board of Directors has unanimously appointed Benjamin E. Bulkley as President and Chief Executive Officer, effective immediately. He succeeds the company's Founder, Jeffrey Carlisle, who will serve as Fluidnet's Chief Innovation Officer.
On behalf of the Board of Directors, Chuck Hadley, Chairman, said, "Fluidnet is fortunate to have Ben to lead the company through FDA clearance of its innovative infusion delivery system and drive the growth of the business. His operating successes in the healthcare IT, life sciences, medical device, and transportation industries represent a perfect mix for Fluidnet. His track record growing global businesses and delivering highly reliable, interconnected systems will pay great dividends for the doctors, nurses, and patients that rely on these systems every day."
According to the FDA, more than 56,000 adverse events and over 700 patient deaths over the past five years have been attributed to faulty infusion system design. The Fluidnet system, once cleared, will offer a transformational change in performance. Based on a decade of user-driven innovation, its architecture is the marriage of advanced fluidics, consumer electronics, and state-of-the-art software development methods.
"The opportunity to substantially improve the safety, usability, and reliability of infusion therapy is striking," said Mr. Bulkley. "Providers and regulators are clearly demanding an easier-to-use and more trustworthy solution. I am very excited to be joining such a strong team dedicated to this mission."
Fluidnet closed a Series B financing round of $9.1 million in March of this year to fund ongoing product development, regulatory, and market preparation efforts. The worldwide market for advanced IV delivery systems and accessories is estimated at $3 billion.
Mr. Bulkley was most recently the Chief Operating Officer of Allscripts, a leader in software, services, and connectivity solutions for healthcare providers. He previously led the global commercial operations of Invitrogen, an innovator of biological tools for life science research. He joined Invitrogen after 16 years with the General Electric Company in a variety of leadership roles in the healthcare, energy and transportation fields, ultimately leading the global service business for GE's healthcare IT division. Mr. Bulkley began his career in systems engineering and program management roles innovating high reliability, low cost solutions in the transportation industry.
Mr. Bulkley holds a Bachelor of Science degree in Electrical Engineering from the University of Connecticut and a Masters degree in Systems Engineering from Gannon University in Pennsylvania.
About Fluidnet
Fluidnet is a developer of advanced IV infusion system solutions that address the growing workflow, connectivity, safety, and regulatory demands across most clinical areas of care. The company currently is finishing the product development, validation, and verification effort, and preparing to submit its 510(k) pre-market notification to the FDA for a multi-use product platform. The system will fully comply with the guidance requirements issued under the agency's new "Infusion Pump Improvement Initiative". For more information see: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/GeneralHospitalDevicesandSupplies/InfusionPumps/ucm205424.htm
SOURCE Fluidnet Corporation
Advertisement
On behalf of the Board of Directors, Chuck Hadley, Chairman, said, "Fluidnet is fortunate to have Ben to lead the company through FDA clearance of its innovative infusion delivery system and drive the growth of the business. His operating successes in the healthcare IT, life sciences, medical device, and transportation industries represent a perfect mix for Fluidnet. His track record growing global businesses and delivering highly reliable, interconnected systems will pay great dividends for the doctors, nurses, and patients that rely on these systems every day."
Advertisement
According to the FDA, more than 56,000 adverse events and over 700 patient deaths over the past five years have been attributed to faulty infusion system design. The Fluidnet system, once cleared, will offer a transformational change in performance. Based on a decade of user-driven innovation, its architecture is the marriage of advanced fluidics, consumer electronics, and state-of-the-art software development methods.
"The opportunity to substantially improve the safety, usability, and reliability of infusion therapy is striking," said Mr. Bulkley. "Providers and regulators are clearly demanding an easier-to-use and more trustworthy solution. I am very excited to be joining such a strong team dedicated to this mission."
Fluidnet closed a Series B financing round of $9.1 million in March of this year to fund ongoing product development, regulatory, and market preparation efforts. The worldwide market for advanced IV delivery systems and accessories is estimated at $3 billion.
Mr. Bulkley was most recently the Chief Operating Officer of Allscripts, a leader in software, services, and connectivity solutions for healthcare providers. He previously led the global commercial operations of Invitrogen, an innovator of biological tools for life science research. He joined Invitrogen after 16 years with the General Electric Company in a variety of leadership roles in the healthcare, energy and transportation fields, ultimately leading the global service business for GE's healthcare IT division. Mr. Bulkley began his career in systems engineering and program management roles innovating high reliability, low cost solutions in the transportation industry.
Mr. Bulkley holds a Bachelor of Science degree in Electrical Engineering from the University of Connecticut and a Masters degree in Systems Engineering from Gannon University in Pennsylvania.
About Fluidnet
Fluidnet is a developer of advanced IV infusion system solutions that address the growing workflow, connectivity, safety, and regulatory demands across most clinical areas of care. The company currently is finishing the product development, validation, and verification effort, and preparing to submit its 510(k) pre-market notification to the FDA for a multi-use product platform. The system will fully comply with the guidance requirements issued under the agency's new "Infusion Pump Improvement Initiative". For more information see: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/GeneralHospitalDevicesandSupplies/InfusionPumps/ucm205424.htm
SOURCE Fluidnet Corporation
